Vaccine-Associated Neurological Adverse Events: A Case Report and Literature Review

Author(s): Maoqiang Tian, Jing Yang, Lei Li, Juan Li, Wenting Lei, Xiaomei Shu*

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 43 , 2019

Become EABM
Become Reviewer

Abstract:

Vaccination is an effective strategy to reduce the burden of preventable illness. However, many clinical reports revealed that various vaccinations may associate with neurological disorders, mainly including autoimmune disease, febrile seizure, and vaccine-associated paralytic poliomyelitis (VAPP). Although more and more reports revealed that part of the above post-vaccine neurological disorders is not directly related to vaccination, it may be merely a coincidence. However, these reports may increase the hesitancy on vaccination for the public population and influence the coverage of vaccination. In this report, we described a child with acute flaccid paralysis possibly caused by a poliovirus vaccine. To provide feasible ways to realize or reduce the risk of neurological adverse events caused by vaccines, we further provide a mini-review of the literature of vaccination associated with neurological adverse events. This revealed that oral poliomyelitis vaccine use exclusively and type 2 serotype poliomyelitis vaccine virus were the risk factors for VAPP. The combination vaccine was associated with an increased risk of ADEM and FS following immunization when compared with the administration of vaccines separately. Even though cases have been reported that vaccination may be a trigger of anti-NMDARe and GBS, there is no direct evidence to prove that vaccination increased the risk of GBS and anti-NMDARe.

Keywords: Vaccinations, neurological disorders, febrile seizure, vaccine-associated paralytic poliomyelitis, encephalitis, Guillain-Barre syndrome.

[1]
Global Polio Eradication Initiative: annual report 2016 Geneva, Switzerland: World Health Organization.; Available at. https://apps.who.int/iris/handle/10665/276236
[2]
Polio Global Eradication Initiative Geneva, Switzerland: World Health Organization 2017 Available at. http://polioeradication.org/polio-today/polio-now/
[3]
Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48(27): 577-81.
[PMID: 10428095]
[4]
Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 2002; 15(3): 333-8.
[http://dx.doi.org/10.1097/00019052-200206000-00018] [PMID: 12045734]
[5]
Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014; 210(Suppl. 1): S380-9.
[http://dx.doi.org/10.1093/infdis/jiu184] [PMID: 25316859]
[6]
Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009; 27(20): 2649-52.
[http://dx.doi.org/10.1016/j.vaccine.2009.02.071] [PMID: 19428874]
[7]
Hosoda M, Inoue H, Miyazawa Y, Kusumi E, Shibuya K. Vaccine-associated paralytic poliomyelitis in Japan. Lancet 2012; 379(9815): 520.
[http://dx.doi.org/10.1016/S0140-6736(12)60232-3] [PMID: 22325660]
[8]
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10(1): 63-74.
[http://dx.doi.org/10.1016/S1474-4422(10)70253-2] [PMID: 21163445]
[9]
Hofmann C, Baur MO, Schroten H. Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: cause or coincidence? J Neurol 2011; 258(3): 500-1.
[http://dx.doi.org/10.1007/s00415-010-5757-3] [PMID: 20878418]
[10]
Blitshteyn S, Brook J. Postural tachycardia syndrome (POTS) with anti-NMDA receptor antibodies after human papillomavirus vaccination. Immunol Res 2017; 65(1): 282-4.
[http://dx.doi.org/10.1007/s12026-016-8855-1] [PMID: 27561785]
[11]
Beirão P, Pereira P, Nunes A, Antunes P. Yellow fever vaccine-associated neurological disease, a suspicious case. BMJ Case Rep 2017; 2017 pii: bcr2016218706
[http://dx.doi.org/10.1136/bcr-2016-218706] [PMID: 28254833]
[12]
Wang H. Anti-NMDA receptor encephalitis and vaccination. Int J Mol Sci 2017; 18(1): 193.
[http://dx.doi.org/10.3390/ijms18010193] [PMID: 28106787]
[13]
Wang H. A protocol for investigating the association of vaccination and anti-NMDA receptor encephalitis. Front Biosci (Schol Ed) 2018; 10: 229-37.
[http://dx.doi.org/10.2741/s511] [PMID: 28930529]
[14]
Tian M, Li J, Lei W, Shu X. Japanese encephalitis virus-induced Anti-N-Methyl-D-Aspartate receptor encephalitis: a case report and review of literature. Neuropediatrics 2019; 50(2): 111-5.
[http://dx.doi.org/10.1055/s-0038-1675607] [PMID: 30620950]
[15]
Maisonneuve AR, Witteman HO, Brehaut J, Dubé È, Wilson K. Educating children and adolescents about vaccines: a review of current literature. Expert Rev Vaccines 2018; 17(4): 311-21.
[http://dx.doi.org/10.1080/14760584.2018.1456921] [PMID: 29569498]
[16]
Incecik F, Ozlem Hergüner M, Altunbasak S. Guillain-Barré syndrome in children. Neurol Sci 2011; 32(3): 381-5.
[http://dx.doi.org/10.1007/s10072-010-0434-y] [PMID: 20953812]
[17]
Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Bull World Health Organ 2000; 78(2): 178-85.
[PMID: 10743282]
[18]
Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009; 27(32): 4278-83.
[http://dx.doi.org/10.1016/j.vaccine.2009.05.023] [PMID: 19450636]
[19]
Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine 2013; 31(44): 5041-6.
[http://dx.doi.org/10.1016/j.vaccine.2013.08.087] [PMID: 24021304]
[20]
Zhao D, Ma R, Zhou T, et al. Introduction of inactivated poliovirus vaccine and impact on vaccine-associated paralytic poliomyelitis-beijing, china, 2014-2016. MMWR Morb Mortal Wkly Rep 2017; 66(49): 1357-61.
[http://dx.doi.org/10.15585/mmwr.mm6649a4] [PMID: 29240729]
[21]
Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257(10): 1335-40.
[http://dx.doi.org/10.1001/jama.1987.03390100073029] [PMID: 3029445]
[22]
Estívariz CF, Molnár Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011; 174(3): 316-25.
[http://dx.doi.org/10.1093/aje/kwr070] [PMID: 21685412]
[23]
Halpern MS, Altamirano J, Maldonado Y. Pediatric HIV infection and decreased prevalence of OPV point mutations linked to vaccine-associated paralytic poliomyelitis. Clin Infect Dis 2018; 67(Suppl. 1): S78-84.
[http://dx.doi.org/10.1093/cid/ciy635] [PMID: 30376083]
[24]
Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014; 89(9): 73-92.
[PMID: 24707513]
[25]
Ye H, Huang T, Ying ZF, et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (I+III) in different dosage forms]. Zhonghua Yu Fang Yi Xue Za Zhi 2018; 52(1): 43-9.
[PMID: 29334707]
[26]
Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived polioviruses - worldwide, january 2017-june 2018. MMWR Morb Mortal Wkly Rep 2018; 67(42): 1189-94.
[http://dx.doi.org/10.15585/mmwr.mm6742a5] [PMID: 30359342]
[27]
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12(2): 157-65.
[http://dx.doi.org/10.1016/S1474-4422(12)70310-1] [PMID: 23290630]
[28]
Remy KE, Custer JW, Cappell J, et al. Pediatric anti-N-methyl-Daspartate receptor encephalitis: a review with pooled analysis and critical care emphasis. Front Pediatr 2017; 5: 250.
[http://dx.doi.org/10.3389/fped.2017.00250] [PMID: 29226117]
[29]
Scheer S, John RM. Anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. J Pediatr Health Care 2016; 30(4): 347-58.
[http://dx.doi.org/10.1016/j.pedhc.2015.09.004] [PMID: 26507948]
[30]
Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72(6): 902-11.
[http://dx.doi.org/10.1002/ana.23689] [PMID: 23280840]
[31]
Xu CL, Liu L, Zhao WQ, et al. Anti-N-methyl-D-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein-Barr virus viral capsid antigen: a case report and one year follow-up. BMC Neurol 2011; 11(01): 149.
[http://dx.doi.org/10.1186/1471-2377-11-149] [PMID: 22126669]
[32]
Bektaş Ö, Tanyel T, Kocabaş BA, Fitöz S, Ince E, Deda G. Anti-N-methyl-D-aspartate receptor encephalitis that developed after herpes encephalitis: a case report and literature review. Neuropediatrics 2014; 45(6): 396-401.
[http://dx.doi.org/10.1055/s-0034-1387813] [PMID: 25261793]
[33]
Patarata E, Bernardino V, Martins A, Pereira R, Loureiro C, Moraes-Fontes MF. Anti-N-methyl-D-aspartate receptor encephalitis in HIV infection. Case Rep Neurol 2016; 8(3): 251-7.
[http://dx.doi.org/10.1159/000453545] [PMID: 28101036]
[34]
Nosadini M, Mohammad SS, Corazza F, et al. Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol 2017; 59(8): 796-805.
[http://dx.doi.org/10.1111/dmcn.13448] [PMID: 28439890]
[35]
Ma J, Zhang T, Jiang L. Japanese encephalitis can trigger anti-N-methyl-D-aspartate receptor encephalitis. J Neurol 2017; 264(6): 1127-31.
[http://dx.doi.org/10.1007/s00415-017-8501-4] [PMID: 28470592]
[36]
Ohya T, Nagamitsu S, Yamashita Y, Matsuishi T. Serial magnetic resonance imaging and single photon emission computed tomography study of acute disseminated encephalomyelitis patient after Japanese encephalitis vaccination. Kurume Med J 2007; 54(3-4): 95-9.
[37]
Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009; 72(3): 232-9.
[http://dx.doi.org/10.1212/01.wnl.0000339482.84392.bd] [PMID: 19153370]
[38]
Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23(8): 756-64.
[http://dx.doi.org/10.1097/01.inf.0000133048.75452.dd] [PMID: 15295226]
[39]
Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol 2012; 259(9): 1929-35.
[http://dx.doi.org/10.1007/s00415-012-6441-6] [PMID: 22349866]
[40]
Xiong CH, Yan Y, Liao Z, et al. Epidemiological characteristics of acute disseminated encephalomyelitis in Nanchang, China: a retrospective study. BMC Public Health 2014; 14: 111.
[http://dx.doi.org/10.1186/1471-2458-14-111] [PMID: 24495742]
[41]
Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol 2007; 20(3): 247-54.
[http://dx.doi.org/10.1097/WCO.0b013e3280f31b45] [PMID: 17495616]
[42]
Hemachudha T, Phanuphak P, Johnson RT, Griffin DE, Ratanavongsiri J, Siriprasomsup W. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 1987; 37(4): 550-6.
[http://dx.doi.org/10.1212/WNL.37.4.550] [PMID: 2436091]
[43]
Ubol S, Hemachudha T, Whitaker JN, Griffin DE. Antibody to peptides of human myelin basic protein in post-rabies vaccine encephalomyelitis sera. J Neuroimmunol 1990; 26(2): 107-11.
[http://dx.doi.org/10.1016/0165-5728(90)90081-W] [PMID: 1688875]
[44]
Garg RK. Acute disseminated encephalomyelitis. Postgrad Med J 2003; 79(927): 11-7.
[http://dx.doi.org/10.1136/pmj.79.927.11] [PMID: 12566545]
[45]
Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008; 15(12): 1315-22.
[http://dx.doi.org/10.1016/j.jocn.2008.05.002] [PMID: 18976924]
[46]
Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72(24): 2132-3.
[http://dx.doi.org/10.1212/WNL.0b013e3181aa53bb] [PMID: 19528522]
[47]
Bomprezzi R, Wildemann B. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2010; 74(864): 2132-3.
[http://dx.doi.org/10.1212/WNL.0b013e3181d2b508]
[48]
Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13(3): 215-24.
[http://dx.doi.org/10.1016/j.autrev.2013.10.003] [PMID: 24514081]
[49]
Pavone P, Pettoello-Mantovano M, Le Pira A, et al. Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics 2010; 41(6): 246-55.
[http://dx.doi.org/10.1055/s-0031-1271656] [PMID: 21445814]
[50]
Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25(31): 5771-92.
[http://dx.doi.org/10.1016/j.vaccine.2007.04.060] [PMID: 17570566]
[51]
Rath B, Magnus M, Heininger U. Evaluating the Brighton Collaboration case definitions, aseptic meningitis, encephalitis, myelitis, and acute disseminated encephalomyelitis, by systematic analysis of 255 clinical cases. Vaccine 2010; 28(19): 3488-95.
[http://dx.doi.org/10.1016/j.vaccine.2010.02.053] [PMID: 20197145]
[52]
Alexander M, Murthy JM. Acute disseminated encephalomyelitis: Treatment guidelines. Ann Indian Acad Neurol 2011; 14(Suppl. 1): S60-4.
[http://dx.doi.org/10.4103/0972-2327.83095] [PMID: 21847331]
[53]
Shoamanesh A, Traboulsee A. Acute disseminated encephalomyelitis following influenza vaccination. Vaccine 2011; 29(46): 8182-5.
[http://dx.doi.org/10.1016/j.vaccine.2011.08.103] [PMID: 21925561]
[54]
Tomonari A, Tojo A, Adachi D, et al. Acute disseminated encephalomyelitis (ADEM) after allogeneic bone marrow transplantation for acute myeloid leukemia. Ann Hematol 2003; 82(1): 37-40.
[PMID: 12574963]
[55]
Gnanajothy R, Visserman LF, Sena KN. Acute Disseminated Encephalomyelitis following meningococcal vaccination: case report and review of the literature. Conn Med 2017; 81(2): 103-6.
[PMID: 29738155]
[56]
Ketelslegers IA, Visser IE, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler 2011; 17(4): 441-8.
[http://dx.doi.org/10.1177/1352458510390068] [PMID: 21148017]
[57]
Wakerley BR, Uncini A, Yuki N, Bae JS. Guillain-Barré and miller fisher syndromes-new diagnostic classification. Nat Rev Neurol 2014; 10(9): 537-44.
[http://dx.doi.org/10.1038/nrneurol.2014.138] [PMID: 25072194]
[58]
Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014; 58(8): 1149-55.
[http://dx.doi.org/10.1093/cid/ciu005] [PMID: 24415636]
[59]
Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339(25): 1797-802.
[http://dx.doi.org/10.1056/NEJM199812173392501] [PMID: 9854114]
[60]
Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis 2013; 57(2): 197-204.
[http://dx.doi.org/10.1093/cid/cit222] [PMID: 23580737]
[61]
Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013; 381(9876): 1461-8.
[http://dx.doi.org/10.1016/S0140-6736(12)62189-8] [PMID: 23498095]
[62]
Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2018; 67(2): 1-44.
[http://dx.doi.org/10.15585/mmwr.rr6702a1] [PMID: 29702631]
[63]
Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012; 21(12): 1350-8.
[http://dx.doi.org/10.1002/pds.3321] [PMID: 22807266]
[64]
Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2): 1-28.
[PMID: 23515099]
[65]
Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62(8): 1194-8.
[http://dx.doi.org/10.1001/archneur.62.8.1194] [PMID: 16087757]
[66]
Moreno de Flagge N. [Simple febrile seizure, complex seizure, generalized epilepsy with febrile seizure plus, FIRES and new syndromes]. Medicina (B Aires) 2013; 73(Suppl. 1): 63-70.
[PMID: 24072053]
[67]
Li X, Lin Y, Yao G, Wang Y. The influence of vaccine on febrile seizure. Curr Neuropharmacol 2018; 16(1): 59-65.
[PMID: 28745219]
[68]
Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccine. Vaccines 5th ed. 2008.
[69]
Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126(1): e1-8.
[http://dx.doi.org/10.1542/peds.2010-0665] [PMID: 20587679]
[70]
Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27(34): 4656-61.
[http://dx.doi.org/10.1016/j.vaccine.2009.05.056] [PMID: 19520201]
[71]
Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292(3): 351-7.
[http://dx.doi.org/10.1001/jama.292.3.351] [PMID: 15265850]
[72]
Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012; 129(5): 809-14.
[http://dx.doi.org/10.1542/peds.2011-3198] [PMID: 22473362]
[73]
Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project, 2010-2011. Vaccine 2012; 30(11): 2024-31.
[http://dx.doi.org/10.1016/j.vaccine.2012.01.027] [PMID: 22361304]
[74]
Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014; 168(3): 211-9.
[http://dx.doi.org/10.1001/jamapediatrics.2013.4469] [PMID: 24395025]
[75]
Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics 2016; 138(1): 138.
[http://dx.doi.org/10.1542/peds.2016-0320] [PMID: 27273711]
[76]
Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012; 135(Pt. 8): 2329-36.
[http://dx.doi.org/10.1093/brain/aws151] [PMID: 22719002]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 43
Year: 2019
Page: [4570 - 4578]
Pages: 9
DOI: 10.2174/1381612825666191119095132
Price: $65

Article Metrics

PDF: 30
HTML: 7